Quick Answer
LianBio reported Research And Development Expense of $59.76 million for the year ending 2022.
- LianBio showed a decrease of -62.3% in Research And Development Expense from 2021 to 2022.
- This data is from LianBio's annual report (Form 10-K), filed with the SEC on March 28, 2023.
- XBRL data for this metric is available from 2020 to 2022 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2020 to 2022), LianBio's Research And Development Expense has declined by 50.6%.
- Historical annual values: Fiscal year 2022: $59.76 million | Fiscal year 2021: $158.69 million | Fiscal year 2020: $120.89 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: